PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
34009973-1	2021	Tumor susceptibility gene 101 (TSG101) is involved in endosomal maturation and has been implicated in the transcriptional regulation of several steroid hormone receptors, although a detailed characterization of such regulation has yet to be conducted.	Steroids	144-151	tumor susceptibility 101	Homo sapiens	0-29
33781846-3	2021	Characterization of keratinocyte-derived EVs after poly(I:C) treatment (poly(I:C)-EVs) showed slight differences in levels of EV markers TSG101 and Alix, a loss of CD63 and were positive for autophagosome marker LC3b-II and the cytokine IL36gamma compared to EVs from unstimulated keratinocytes (control-EVs).	poly(i:c)-evs	72-85	tumor susceptibility 101	Homo sapiens	137-143
34009973-1	2021	Tumor susceptibility gene 101 (TSG101) is involved in endosomal maturation and has been implicated in the transcriptional regulation of several steroid hormone receptors, although a detailed characterization of such regulation has yet to be conducted.	Steroids	144-151	tumor susceptibility 101	Homo sapiens	31-37
34009973-2	2021	Here we directly measure binding of TSG101 to one steroid hormone receptor, the glucocorticoid receptor (GR).	Steroids	50-57	tumor susceptibility 101	Homo sapiens	36-42
33623047-0	2021	An ESCRT-dependent step in fatty acid transfer from lipid droplets to mitochondria through VPS13D-TSG101 interactions.	Fatty Acids	27-37	tumor susceptibility 101	Homo sapiens	98-104
33853959-0	2021	Prazoles Targeting Tsg101 Inhibit Release of Epstein-Barr Virus following Reactivation from Latency.	prazoles	0-8	tumor susceptibility 101	Homo sapiens	19-25
33853959-4	2021	Previously, we reported that the proton pump inhibitor Tenatoprazole, which blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV.	Tenatoprazole	55-68	tumor susceptibility 101	Homo sapiens	136-142
33853959-7	2021	Replacement of endogenous Tsg101 with a mutant Tsg101 refractory to prazole-mediated inhibition rescued EBV release.	Lorpiprazole	68-75	tumor susceptibility 101	Homo sapiens	26-32
33853959-7	2021	Replacement of endogenous Tsg101 with a mutant Tsg101 refractory to prazole-mediated inhibition rescued EBV release.	Lorpiprazole	68-75	tumor susceptibility 101	Homo sapiens	47-53
33731460-0	2021	Ilaprazole and other novel prazole-based compounds that bind Tsg101 inhibit viral budding of HSV-1/2 and HIV from cells.	ilaprazole	0-10	tumor susceptibility 101	Homo sapiens	61-67
33731460-0	2021	Ilaprazole and other novel prazole-based compounds that bind Tsg101 inhibit viral budding of HSV-1/2 and HIV from cells.	Lorpiprazole	3-10	tumor susceptibility 101	Homo sapiens	61-67
33731460-3	2021	The prazole drug, tenatoprazole, was previously shown to bind to ESCRT complex member Tsg101 and to quantitatively block the release of infectious HIV-1 from cells in culture.	Lorpiprazole	4-11	tumor susceptibility 101	Homo sapiens	86-92
33731460-3	2021	The prazole drug, tenatoprazole, was previously shown to bind to ESCRT complex member Tsg101 and to quantitatively block the release of infectious HIV-1 from cells in culture.	Tenatoprazole	18-31	tumor susceptibility 101	Homo sapiens	86-92
33731460-7	2021	Our results indicate that prazole-based compounds may represent a class of drugs with potential to be broad-spectrum antiviral agents against multiple enveloped viruses, by interrupting cellular Tsg101 interaction with maturing virus, thus blocking the budding process that releases particles from the cell.ImportanceThese results provide the basis for the development of drugs that target enveloped virus budding that can be used ultimately to control multiple virus infections in humans.	Lorpiprazole	26-33	tumor susceptibility 101	Homo sapiens	195-201
33525864-12	2021	RT-PCR analysis of EV biogenesis markers (CD63, CD81, Alix, TSG101, Syntenin1, ADAM10, RAB27b, and Syndecan) showed differential expression between the iron-oxide-treated cultures and nontreated cultures, as well as between adherent and nonadherent 3D cultures.	ferric oxide	152-162	tumor susceptibility 101	Homo sapiens	60-66
32994219-2	2020	Two ESCRT proteins, TSG101 and ALIX, bind to the Gag C-terminal p6 peptide.	Peptides	67-74	tumor susceptibility 101	Homo sapiens	20-26
33338748-0	2021	Tumor Susceptibility Gene 101 facilitates rapamycin-induced autophagic flux in neuron cells.	Sirolimus	42-51	tumor susceptibility 101	Homo sapiens	0-29
33338748-6	2021	Our results showed that TSG101 expression was slightly increased in neuron cells when exposed to rapamycin.	Sirolimus	97-106	tumor susceptibility 101	Homo sapiens	24-30
33338748-8	2021	Rapamycin-elevated MAP1LC3-II turnover and RFP+Wasabi- puncta were repressed in TSG101 silenced cells, indicating that TSG101 is involved in rapamycin-induced autophagic flux in cells.	Sirolimus	0-9	tumor susceptibility 101	Homo sapiens	80-86
33338748-8	2021	Rapamycin-elevated MAP1LC3-II turnover and RFP+Wasabi- puncta were repressed in TSG101 silenced cells, indicating that TSG101 is involved in rapamycin-induced autophagic flux in cells.	Sirolimus	0-9	tumor susceptibility 101	Homo sapiens	119-125
33338748-8	2021	Rapamycin-elevated MAP1LC3-II turnover and RFP+Wasabi- puncta were repressed in TSG101 silenced cells, indicating that TSG101 is involved in rapamycin-induced autophagic flux in cells.	Sirolimus	141-150	tumor susceptibility 101	Homo sapiens	80-86
33338748-8	2021	Rapamycin-elevated MAP1LC3-II turnover and RFP+Wasabi- puncta were repressed in TSG101 silenced cells, indicating that TSG101 is involved in rapamycin-induced autophagic flux in cells.	Sirolimus	141-150	tumor susceptibility 101	Homo sapiens	119-125
33338748-10	2021	Taken together, our results suggested that TSG101 might be required for amphisome formation to promote autophagic flux in neuron cells when exposed to rapamycin.	Sirolimus	151-160	tumor susceptibility 101	Homo sapiens	43-49
33224932-9	2020	Detection of the luminal membrane protein TSG101 with antibodies depended on membrane permeabilization, consistent with the presence of vesicles on the chip.	Phenobarbital	17-24	tumor susceptibility 101	Homo sapiens	42-48
32622655-12	2020	RESULT(S): RIF-EVs and FER-EVs are bilayered vesicles ~100 nm in size and enriched with TSG101, Alix, and CD9.	rif-evs	11-18	tumor susceptibility 101	Homo sapiens	88-94
32917811-0	2020	Proline-rich domain of human ALIX contains multiple TSG101-UEV interaction sites and forms phosphorylation-mediated reversible amyloids.	Proline	0-7	tumor susceptibility 101	Homo sapiens	52-58
32917811-4	2020	It contains three tandem sequentially similar proline-rich motifs that compete for a single binding site on its signaling partner, TSG101-UEV, as evidenced by heteronuclear NMR spectroscopy.	Proline	46-53	tumor susceptibility 101	Homo sapiens	131-137
32998394-0	2020	Cyclic Peptide Inhibitors of the Tsg101 UEV Protein Interactions Refined through Global Docking and Gaussian Accelerated Molecular Dynamics Simulations.	Peptides, Cyclic	0-14	tumor susceptibility 101	Homo sapiens	33-39
32919085-0	2020	ESCRT-I Component VPS23A Is Targeted by E3 Ubiquitin Ligase XBAT35 for Proteasome-Mediated Degradation in Modulating ABA Signaling.	alisol B 23-acetate	117-120	tumor susceptibility 101	Homo sapiens	18-23
32622655-12	2020	RESULT(S): RIF-EVs and FER-EVs are bilayered vesicles ~100 nm in size and enriched with TSG101, Alix, and CD9.	fer-evs	23-30	tumor susceptibility 101	Homo sapiens	88-94
31336913-6	2019	Targeting leptin signaling, by a selective leptin receptor antagonist the peptide LDFI (Leu-Asp-Phe-Ile), abrogated leptin effects on Tsg101 expression and on exosome secretion in breast cancer cells.	leu-asp-phe-ile	88-103	tumor susceptibility 101	Homo sapiens	134-140
32231660-12	2020	The measurement of circulating NK exosomes in the plasma of melanoma patients and healthy donors evidenced lower levels of tsg101+CD56+ exosomes in patients with respect to donors.	nk	31-33	tumor susceptibility 101	Homo sapiens	123-129
30068652-7	2018	Using a molecular dynamic simulation, we observed that both gag-PTAP and ORF3-PSAP motifs bind to the same site in UEV-TSG101 by hydrogen bonding.	Glycosaminoglycans	60-63	tumor susceptibility 101	Homo sapiens	119-125
30873590-6	2019	Moreover, swainsonine reduces CD133 secretion by reducing its mono-ubiquitination and inhibiting the interaction between CD133 and Tsg101.	Swainsonine	10-21	tumor susceptibility 101	Homo sapiens	131-137
30068652-7	2018	Using a molecular dynamic simulation, we observed that both gag-PTAP and ORF3-PSAP motifs bind to the same site in UEV-TSG101 by hydrogen bonding.	1-(4-methylphenyl)propane-2-amine	64-68	tumor susceptibility 101	Homo sapiens	119-125
30068652-7	2018	Using a molecular dynamic simulation, we observed that both gag-PTAP and ORF3-PSAP motifs bind to the same site in UEV-TSG101 by hydrogen bonding.	Hydrogen	129-137	tumor susceptibility 101	Homo sapiens	119-125
30068652-8	2018	HIV-released inhibitory CPs also displayed binding to the same site in UEV-TSG101, indicating that they may compete with ORF3-PSAP or gag-PTAP for binding to UEV-TSG101.	Glycosaminoglycans	134-137	tumor susceptibility 101	Homo sapiens	75-81
30068652-8	2018	HIV-released inhibitory CPs also displayed binding to the same site in UEV-TSG101, indicating that they may compete with ORF3-PSAP or gag-PTAP for binding to UEV-TSG101.	Glycosaminoglycans	134-137	tumor susceptibility 101	Homo sapiens	162-168
30068652-8	2018	HIV-released inhibitory CPs also displayed binding to the same site in UEV-TSG101, indicating that they may compete with ORF3-PSAP or gag-PTAP for binding to UEV-TSG101.	1-(4-methylphenyl)propane-2-amine	138-142	tumor susceptibility 101	Homo sapiens	75-81
30068652-8	2018	HIV-released inhibitory CPs also displayed binding to the same site in UEV-TSG101, indicating that they may compete with ORF3-PSAP or gag-PTAP for binding to UEV-TSG101.	1-(4-methylphenyl)propane-2-amine	138-142	tumor susceptibility 101	Homo sapiens	162-168
29571744-0	2018	The NC domain of HIV-1 Gag contributes to the interaction of Gag with TSG101.	Glycosaminoglycans	23-26	tumor susceptibility 101	Homo sapiens	70-76
29859188-6	2018	Furthermore, chloroquine or bafilomycin A1 treatment was able to restore TSG101-mediated AR expression reduction.	Chloroquine	13-24	tumor susceptibility 101	Homo sapiens	73-79
29859188-6	2018	Furthermore, chloroquine or bafilomycin A1 treatment was able to restore TSG101-mediated AR expression reduction.	bafilomycin	28-39	tumor susceptibility 101	Homo sapiens	73-79
29571744-0	2018	The NC domain of HIV-1 Gag contributes to the interaction of Gag with TSG101.	Glycosaminoglycans	61-64	tumor susceptibility 101	Homo sapiens	70-76
29571744-4	2018	To investigate the role of GagNC in this recruitment, we analysed its impact on TSG101 and ALIX localisations and interactions in cells expressing Gag.	Glycosaminoglycans	27-30	tumor susceptibility 101	Homo sapiens	80-86
29571744-7	2018	RESULTS: We show that deletion of NC or of its two zinc fingers decreases the amount of Gag-TSG101 interacting complexes in cells.	Glycosaminoglycans	88-91	tumor susceptibility 101	Homo sapiens	92-98
29571744-10	2018	CONCLUSION: The NC zinc fingers and p6 domain of Gag participate in the formation of the Gag-TSG101 complex and in its cellular localisation.	Glycosaminoglycans	49-52	tumor susceptibility 101	Homo sapiens	93-99
29571744-10	2018	CONCLUSION: The NC zinc fingers and p6 domain of Gag participate in the formation of the Gag-TSG101 complex and in its cellular localisation.	Glycosaminoglycans	89-92	tumor susceptibility 101	Homo sapiens	93-99
29571744-12	2018	In addition, details on the Gag-TSG101 complex were obtained by combining two high resolution biophysical techniques.	Glycosaminoglycans	28-31	tumor susceptibility 101	Homo sapiens	32-38
27856401-0	2016	ESCRT-I Component VPS23A Affects ABA Signaling by Recognizing ABA Receptors for Endosomal Degradation.	Abscisic Acid	33-36	tumor susceptibility 101	Homo sapiens	18-23
27648839-2	2016	However, some reports show that overexpression of TSG101 inhibits virus release by disruption of Gag targeting process.	Glycosaminoglycans	97-100	tumor susceptibility 101	Homo sapiens	50-56
27648839-5	2016	Co-transfection of TSG101 and Gag with Vpr prevented TSG101-induced Gag accumulation in endosomes and lysosomes.	Glycosaminoglycans	30-33	tumor susceptibility 101	Homo sapiens	53-59
27648839-7	2016	Vpr and Gag interaction is required to counteract TSG101 overexpression effect since Vpr A30F mutant which is unable to interact with Gag and incorporate into virions, reduced ability to prevent Gag accumulation and to rescue VLP production.	Glycosaminoglycans	134-137	tumor susceptibility 101	Homo sapiens	50-56
27648839-7	2016	Vpr and Gag interaction is required to counteract TSG101 overexpression effect since Vpr A30F mutant which is unable to interact with Gag and incorporate into virions, reduced ability to prevent Gag accumulation and to rescue VLP production.	Glycosaminoglycans	8-11	tumor susceptibility 101	Homo sapiens	50-56
27648839-7	2016	Vpr and Gag interaction is required to counteract TSG101 overexpression effect since Vpr A30F mutant which is unable to interact with Gag and incorporate into virions, reduced ability to prevent Gag accumulation and to rescue VLP production.	Glycosaminoglycans	134-137	tumor susceptibility 101	Homo sapiens	50-56
27648839-8	2016	In addition, GST pull-down assays and Biacore analysis revealed that Vpr competed with TSG101 for Gag binding.	Glycosaminoglycans	98-101	tumor susceptibility 101	Homo sapiens	87-93
26608825-5	2015	In HT1080 cells, TSG101 depletion increased both baseline and phorbol 12-myristate 13-acetate (PMA)-induced MMP-9 secretion through enhancing MMP-9 mRNA expression, but did not affect the expression or activation of MMP-2.	Tetradecanoylphorbol Acetate	62-93	tumor susceptibility 101	Homo sapiens	17-23
27648839-9	2016	These results indicate that Vpr overcomes the effects of TSG101 overexpression to support viral production by competing with TSG101 to bind Gag.	Glycosaminoglycans	140-143	tumor susceptibility 101	Homo sapiens	57-63
27648839-9	2016	These results indicate that Vpr overcomes the effects of TSG101 overexpression to support viral production by competing with TSG101 to bind Gag.	Glycosaminoglycans	140-143	tumor susceptibility 101	Homo sapiens	125-131
27280284-4	2016	Specifically, we show that Gag mutants with compromised interactions with ALIX and Tsg101, two early ESCRT factors, have an average budding delay of ~75 minutes and ~10 hours, respectively.	Glycosaminoglycans	27-30	tumor susceptibility 101	Homo sapiens	83-89
26608825-5	2015	In HT1080 cells, TSG101 depletion increased both baseline and phorbol 12-myristate 13-acetate (PMA)-induced MMP-9 secretion through enhancing MMP-9 mRNA expression, but did not affect the expression or activation of MMP-2.	Tetradecanoylphorbol Acetate	95-98	tumor susceptibility 101	Homo sapiens	17-23
24904548-0	2014	Tsg101 regulates PI(4,5)P2/Ca(2+) signaling for HIV-1 Gag assembly.	pi(4,5)p2	17-26	tumor susceptibility 101	Homo sapiens	0-6
25682864-7	2015	We detected tetraspanin proteins (CD9, CD63, CD81), Alix and tumor susceptibility gene-101 (TSG101) of exosomal markers from rotenone treated CSCs.	Rotenone	125-133	tumor susceptibility 101	Homo sapiens	92-98
25682864-9	2015	The mRNA expression of CD9, CD63, CD81 and TSG101 analyzed by qRT-PCR showed that the rotenone induced the expression of CD9, CD63, CD81 and TSG101 in CSCs.	Rotenone	86-94	tumor susceptibility 101	Homo sapiens	43-49
25682864-9	2015	The mRNA expression of CD9, CD63, CD81 and TSG101 analyzed by qRT-PCR showed that the rotenone induced the expression of CD9, CD63, CD81 and TSG101 in CSCs.	Rotenone	86-94	tumor susceptibility 101	Homo sapiens	141-147
24904548-7	2014	This property required the PTAP motif in Gag that recruits Tsg101, an ESCRT-1 component.	1-(4-methylphenyl)propane-2-amine	27-31	tumor susceptibility 101	Homo sapiens	59-65
21117030-2	2011	The siRNA against TSG101 was transfected into the breast cancer MCF-7 cell line using Lipofectamine 2000.	Lipofectamine	86-104	tumor susceptibility 101	Homo sapiens	18-24
23816704-15	2013	It might act as an adapter that binds, on the one hand, to LHBs and, on the other hand, to tsg101 and thereby helps recruit the ESCRT machinery to the viral envelope proteins.	Luteinizing Hormone, beta Subunit	59-63	tumor susceptibility 101	Homo sapiens	91-97
23104469-6	2013	The ORF3 protein interacts with the tumor susceptibility gene 101, a critical cellular protein required for the budding of enveloped viruses, through the Pro, Ser, Ala, and Pro (PSAP) motif in infected cells; ORF3 is co-localized with multivesicular bodies (MVBs) in the cytoplasm of infected cells, thus suggesting that HEV requires the MVB pathway for the egress of virus particles.	Serine	159-162	tumor susceptibility 101	Homo sapiens	36-65
23104469-6	2013	The ORF3 protein interacts with the tumor susceptibility gene 101, a critical cellular protein required for the budding of enveloped viruses, through the Pro, Ser, Ala, and Pro (PSAP) motif in infected cells; ORF3 is co-localized with multivesicular bodies (MVBs) in the cytoplasm of infected cells, thus suggesting that HEV requires the MVB pathway for the egress of virus particles.	Alanine	164-167	tumor susceptibility 101	Homo sapiens	36-65
23104469-6	2013	The ORF3 protein interacts with the tumor susceptibility gene 101, a critical cellular protein required for the budding of enveloped viruses, through the Pro, Ser, Ala, and Pro (PSAP) motif in infected cells; ORF3 is co-localized with multivesicular bodies (MVBs) in the cytoplasm of infected cells, thus suggesting that HEV requires the MVB pathway for the egress of virus particles.	Proline	154-157	tumor susceptibility 101	Homo sapiens	36-65
23104469-6	2013	The ORF3 protein interacts with the tumor susceptibility gene 101, a critical cellular protein required for the budding of enveloped viruses, through the Pro, Ser, Ala, and Pro (PSAP) motif in infected cells; ORF3 is co-localized with multivesicular bodies (MVBs) in the cytoplasm of infected cells, thus suggesting that HEV requires the MVB pathway for the egress of virus particles.	psap	178-182	tumor susceptibility 101	Homo sapiens	36-65
21875593-8	2011	However, with Tsg101 bound, Gag release was independent of Gq-mediated activation of PLC, and budding was readily enhanced by pharmacological stimulation of PLC.	glycylglutamine	59-61	tumor susceptibility 101	Homo sapiens	14-20
22438540-6	2012	We also showed that the PSAP motif interacts with the host protein tumor suppressor gene 101 (TSG101) and that altering any proline within the PSAP motif disrupts this interaction.	Proline	124-131	tumor susceptibility 101	Homo sapiens	67-92
22438540-6	2012	We also showed that the PSAP motif interacts with the host protein tumor suppressor gene 101 (TSG101) and that altering any proline within the PSAP motif disrupts this interaction.	Proline	124-131	tumor susceptibility 101	Homo sapiens	94-100
21643473-5	2011	Reported herein are crystal structures of Tsg101 in complex with two structurally-modified PTAP-derived peptides.	1-(4-methylphenyl)propane-2-amine	91-95	tumor susceptibility 101	Homo sapiens	42-48
21643473-5	2011	Reported herein are crystal structures of Tsg101 in complex with two structurally-modified PTAP-derived peptides.	Peptides	104-112	tumor susceptibility 101	Homo sapiens	42-48
22102845-7	2011	We demonstrated the potential broad spectrum activity of a lead candidate inhibitor by demonstrating its ability to block PTAP-dependent binding of HIV-1 Gag to Tsg101 and subsequent egress of HIV-1 Gag VLPs.	1-(4-methylphenyl)propane-2-amine	122-126	tumor susceptibility 101	Homo sapiens	161-167
19210987-4	2009	Glutathione S-transferase pull down experiments and immunoprecipitation revealed that not only connexin45 but also connexin30.2, -36, and -43 carboxyterminal regions were associated with TSG101 protein in pull down analyses and that connexin31, -43 and -45 co-precipitate with endogenous TSG101 protein in lysates from HM1 embryonic stem cells.	Glutathione	0-11	tumor susceptibility 101	Homo sapiens	187-193
19914066-2	2010	Recognition of p6 by Tsg101 is mediated in part by a proline-rich motif that contains the sequence "Pro-Thr-Ala-Pro" ("PTAP").	Proline	53-60	tumor susceptibility 101	Homo sapiens	21-27
19914066-2	2010	Recognition of p6 by Tsg101 is mediated in part by a proline-rich motif that contains the sequence "Pro-Thr-Ala-Pro" ("PTAP").	pro-thr-ala-pro	100-115	tumor susceptibility 101	Homo sapiens	21-27
19914066-2	2010	Recognition of p6 by Tsg101 is mediated in part by a proline-rich motif that contains the sequence "Pro-Thr-Ala-Pro" ("PTAP").	1-(4-methylphenyl)propane-2-amine	119-123	tumor susceptibility 101	Homo sapiens	21-27
20929444-4	2010	Our results demonstrate that an intramolecular interaction between Patch 2 in the Bro1 domain and the TSG101 (tumour susceptibility gene 101 protein)-docking site in the proline-rich domain locks ALIX into a closed conformation that renders ALIX unable to interact with CHMP4 and retroviral Gag proteins.	Proline	170-177	tumor susceptibility 101	Homo sapiens	102-108
20929444-4	2010	Our results demonstrate that an intramolecular interaction between Patch 2 in the Bro1 domain and the TSG101 (tumour susceptibility gene 101 protein)-docking site in the proline-rich domain locks ALIX into a closed conformation that renders ALIX unable to interact with CHMP4 and retroviral Gag proteins.	Proline	170-177	tumor susceptibility 101	Homo sapiens	110-148
20929444-4	2010	Our results demonstrate that an intramolecular interaction between Patch 2 in the Bro1 domain and the TSG101 (tumour susceptibility gene 101 protein)-docking site in the proline-rich domain locks ALIX into a closed conformation that renders ALIX unable to interact with CHMP4 and retroviral Gag proteins.	Glycosaminoglycans	291-294	tumor susceptibility 101	Homo sapiens	102-108
20929444-4	2010	Our results demonstrate that an intramolecular interaction between Patch 2 in the Bro1 domain and the TSG101 (tumour susceptibility gene 101 protein)-docking site in the proline-rich domain locks ALIX into a closed conformation that renders ALIX unable to interact with CHMP4 and retroviral Gag proteins.	Glycosaminoglycans	291-294	tumor susceptibility 101	Homo sapiens	110-148
20399684-4	2010	Using siRNA in primary T cells, we show that Ub recognition by TSG101 is required for cSMAC formation, TCR MC signal termination, TCR downregulation, and segregation of TCR-MHC-peptide from PKC-theta-enriched signaling complexes.	Methylcholanthrene	107-109	tumor susceptibility 101	Homo sapiens	63-69
20004458-2	2010	In this article, we identify two lysines in the tombusvirus p33 replication co-factor involved in ubiquitination and show that the same lysines are also important for the p33 to interact with the host Vps23p ESCRT-I factor.	Lysine	33-40	tumor susceptibility 101	Homo sapiens	201-207
20004458-2	2010	In this article, we identify two lysines in the tombusvirus p33 replication co-factor involved in ubiquitination and show that the same lysines are also important for the p33 to interact with the host Vps23p ESCRT-I factor.	Lysine	136-143	tumor susceptibility 101	Homo sapiens	201-207
19542561-9	2009	Regulation of Tsg101 itself by the ubiquitin ligase TAL (Tsg101-associated ligase) is most likely conferred by a single PSAP binding motif that enables the interaction with Tsg101 UEV.	psap	120-124	tumor susceptibility 101	Homo sapiens	14-20
19542561-9	2009	Regulation of Tsg101 itself by the ubiquitin ligase TAL (Tsg101-associated ligase) is most likely conferred by a single PSAP binding motif that enables the interaction with Tsg101 UEV.	psap	120-124	tumor susceptibility 101	Homo sapiens	57-63
19244744-2	2008	Recent research of TSG101 has revealed that TSG101 aids HIV-1 budding from infected cells by attaching to Gag.	Glycosaminoglycans	106-109	tumor susceptibility 101	Homo sapiens	19-25
19053244-3	2008	Here, we report the use of a bacterial reverse two-hybrid system to identify cyclic peptides that interfere with the Gag-TSG101 interaction and the finding that a five amino acid peptide discovered by this approach can disrupt the interaction and consequently inhibit HIV egress.	Glycosaminoglycans	117-120	tumor susceptibility 101	Homo sapiens	121-127
19053244-7	2008	Our findings, which suggest that interference with the TSG101-Gag interaction by cyclic peptides may be of practical use in the treatment of HIV infections, identify a specific cyclic peptide that reduces VLP release by this mechanism; they also demonstrate that the efficiency of interference with protein-protein interactions by cyclic peptides can be enhanced by tagging the peptides with translocation-promoting sequences.	Glycosaminoglycans	62-65	tumor susceptibility 101	Homo sapiens	55-61
19244744-2	2008	Recent research of TSG101 has revealed that TSG101 aids HIV-1 budding from infected cells by attaching to Gag.	Glycosaminoglycans	106-109	tumor susceptibility 101	Homo sapiens	44-50
18655064-0	2008	SAR by oxime-containing peptide libraries: application to Tsg101 ligand optimization.	Oximes	7-12	tumor susceptibility 101	Homo sapiens	58-64
18643869-6	2008	GISP also inhibits TSG101-dependent GABA(B2) down-regulation in human embryonic kidney 293 cells whereas over-expression of a mutant GISP lacking the TSG101 binding domain has no effect on GABA(B2) degradation.	gamma-Aminobutyric Acid	36-40	tumor susceptibility 101	Homo sapiens	19-25
18077552-5	2008	We show that Tal polyubiquitinates lysine residues in the C-terminus of uncomplexed Tsg101, resulting in proteasomal degradation.	Lysine	35-41	tumor susceptibility 101	Homo sapiens	84-90
18083557-0	2008	Protected aminooxyprolines for expedited library synthesis: application to Tsg101-directed proline-oxime containing peptides.	aminooxyprolines	10-26	tumor susceptibility 101	Homo sapiens	75-81
18083557-0	2008	Protected aminooxyprolines for expedited library synthesis: application to Tsg101-directed proline-oxime containing peptides.	proline-oxime	91-104	tumor susceptibility 101	Homo sapiens	75-81
17321722-4	2007	In addition, we found that TSG101 siRNA inhibits calcium-induced early differentiation of human foreskin keratinocytes, indicating an essential and downstream role for TSG101 in this process.	Calcium	49-56	tumor susceptibility 101	Homo sapiens	27-33
21118645-3	2007	METHODS: Immunohistochemical method (SP method) was adopted to detect the expression of TSG101, P21 and P300/CBP proteins in cancer tissues and neighboring noncancerous tissues of 79 cases of human squamous cell carcinoma and adenocarcinoma of the lung.	TFF2 protein, human	37-39	tumor susceptibility 101	Homo sapiens	88-94
17321722-4	2007	In addition, we found that TSG101 siRNA inhibits calcium-induced early differentiation of human foreskin keratinocytes, indicating an essential and downstream role for TSG101 in this process.	Calcium	49-56	tumor susceptibility 101	Homo sapiens	168-174
17321722-5	2007	Furthermore, the PKC agonist TPA promotes expression of TSG101 and keratin 10 in keratinocytes under low calcium conditions, while co-treatment with the PKC inhibitor GF 109203X blocks TPA-induced TSG101 and keratin 10 upregulation.	Tetradecanoylphorbol Acetate	29-32	tumor susceptibility 101	Homo sapiens	56-62
17321722-5	2007	Furthermore, the PKC agonist TPA promotes expression of TSG101 and keratin 10 in keratinocytes under low calcium conditions, while co-treatment with the PKC inhibitor GF 109203X blocks TPA-induced TSG101 and keratin 10 upregulation.	Tetradecanoylphorbol Acetate	29-32	tumor susceptibility 101	Homo sapiens	197-203
17321722-5	2007	Furthermore, the PKC agonist TPA promotes expression of TSG101 and keratin 10 in keratinocytes under low calcium conditions, while co-treatment with the PKC inhibitor GF 109203X blocks TPA-induced TSG101 and keratin 10 upregulation.	Tetradecanoylphorbol Acetate	185-188	tumor susceptibility 101	Homo sapiens	197-203
17321722-7	2007	Here we show that both calcium and TPA activate PKC, stimulate phosphorylation of Sp1, and augment the activity of the TSG101 promoter in a manner dependent on its Sp1-binding site.	Calcium	23-30	tumor susceptibility 101	Homo sapiens	119-125
17321722-7	2007	Here we show that both calcium and TPA activate PKC, stimulate phosphorylation of Sp1, and augment the activity of the TSG101 promoter in a manner dependent on its Sp1-binding site.	Tetradecanoylphorbol Acetate	35-38	tumor susceptibility 101	Homo sapiens	119-125
17321722-9	2007	Taken together, these data suggest that an intracellular calcium store independent PKC-Sp1 signaling pathway induces early keratinocyte differentiation through upregulation of TSG101.	Calcium	57-64	tumor susceptibility 101	Homo sapiens	176-182
16004603-6	2005	Using various deletion mutants of TSG101, the central PRR (proline-rich region) was found to be sufficient for interaction with ALG-2 by the GST-pull-down assay.	Proline	59-66	tumor susceptibility 101	Homo sapiens	34-40
16552148-1	2006	The UEV domain of the TSG101 protein functions in the vacuolar protein-sorting pathway and in the budding process of HIV-1 and other retroviruses by recognizing ubiquitin in proteins tagged for degradation and short sequences in viral proteins containing an essential and well conserved PTAP motif, respectively.	1-(4-methylphenyl)propane-2-amine	287-291	tumor susceptibility 101	Homo sapiens	22-28
16552148-4	2006	TSG101-UEV was crystallized in the presence of PEG 4000 and ammonium sulfate.	Polyethylene Glycols	47-50	tumor susceptibility 101	Homo sapiens	0-6
16552148-4	2006	TSG101-UEV was crystallized in the presence of PEG 4000 and ammonium sulfate.	Ammonium Sulfate	60-76	tumor susceptibility 101	Homo sapiens	0-6
17428861-2	2007	HIV-1 harbors a PTAP-type L domain in the p6 region of Gag that engages an endosomal budding machinery through Tsg101.	Glycosaminoglycans	55-58	tumor susceptibility 101	Homo sapiens	111-117
17229889-3	2007	Here, we report the identification of TSG101, a key component of the endosomal sorting complex required for transport (ESCRT)-I, as a specific Mahogunin substrate.	mahogunin	143-152	tumor susceptibility 101	Homo sapiens	38-44
17229889-4	2007	We find that Mahogunin interacts with the ubiquitin E2 variant (UEV) domain of TSG101 via its PSAP motif and that it catalyzes monoubiquitylation of TSG101 both in vivo and in vitro.	mahogunin	13-22	tumor susceptibility 101	Homo sapiens	79-85
17229889-4	2007	We find that Mahogunin interacts with the ubiquitin E2 variant (UEV) domain of TSG101 via its PSAP motif and that it catalyzes monoubiquitylation of TSG101 both in vivo and in vitro.	mahogunin	13-22	tumor susceptibility 101	Homo sapiens	149-155
17182674-5	2007	Coimmunoprecipitation analysis showed that the expression of Hrs mutant dFYVE or ASAA significantly reduced or abolished the HIV-1 Gag-Tsg101 interaction.	asaa	81-85	tumor susceptibility 101	Homo sapiens	135-141
17182674-6	2007	Yeast-two hybrid assays were used to identify two new and independent Tsg101 binding sites, one in the Hrs coiled-coil domain and one in the proline/glutamic acid-rich domain.	Proline	141-148	tumor susceptibility 101	Homo sapiens	70-76
17182674-6	2007	Yeast-two hybrid assays were used to identify two new and independent Tsg101 binding sites, one in the Hrs coiled-coil domain and one in the proline/glutamic acid-rich domain.	Glutamic Acid	149-162	tumor susceptibility 101	Homo sapiens	70-76
17048869-0	2006	Hydrazone- and hydrazide-containing N-substituted glycines as peptoid surrogates for expedited library synthesis: application to the preparation of Tsg101-directed HIV-1 budding antagonists.	Hydrazones	0-9	tumor susceptibility 101	Homo sapiens	148-154
17048869-0	2006	Hydrazone- and hydrazide-containing N-substituted glycines as peptoid surrogates for expedited library synthesis: application to the preparation of Tsg101-directed HIV-1 budding antagonists.	Isoniazid	15-24	tumor susceptibility 101	Homo sapiens	148-154
17048869-0	2006	Hydrazone- and hydrazide-containing N-substituted glycines as peptoid surrogates for expedited library synthesis: application to the preparation of Tsg101-directed HIV-1 budding antagonists.	N-substituted Glycines	36-58	tumor susceptibility 101	Homo sapiens	148-154
16004603-7	2005	Direct binding of ALG-2 to the TSG101 PRR was demonstrated by an overlay assay using biotin-labelled ALG-2 as a probe.	Biotin	85-91	tumor susceptibility 101	Homo sapiens	31-37
15731271-4	2005	It was recently demonstrated that expression of a C-terminal fragment of TSG101 (TSG-3") blocked the budding of both PTAP-dependent and PPPY-dependent retroviruses.	1-(4-methylphenyl)propane-2-amine	117-121	tumor susceptibility 101	Homo sapiens	73-79
15795524-0	2005	Gag-p6 Tsg101 binding site duplications in maternal-infant HIV infection.	Glycosaminoglycans	0-3	tumor susceptibility 101	Homo sapiens	7-13
15197357-5	2004	Shen et al reported that transient transfection of TSG101 siRNA reduced the expression level of TSG101 protein as well as resistance to vincristine and adriamycin in gastric cancer cells.	Vincristine	136-147	tumor susceptibility 101	Homo sapiens	51-57
15044860-1	2004	We have previously identified tumor susceptibility gene101 (TSG101), overexpressed in vincristine-resistant human gastric adenocarcinoma cell line SGC7901/VCR using a modified subtractive hybridization method and Western blot.	Vincristine	86-97	tumor susceptibility 101	Homo sapiens	30-58
15197357-5	2004	Shen et al reported that transient transfection of TSG101 siRNA reduced the expression level of TSG101 protein as well as resistance to vincristine and adriamycin in gastric cancer cells.	Doxorubicin	152-162	tumor susceptibility 101	Homo sapiens	51-57
15044860-1	2004	We have previously identified tumor susceptibility gene101 (TSG101), overexpressed in vincristine-resistant human gastric adenocarcinoma cell line SGC7901/VCR using a modified subtractive hybridization method and Western blot.	Vincristine	86-97	tumor susceptibility 101	Homo sapiens	60-66
15163754-10	2004	However, MA showed binding to TSG101 in the yeast two-hybrid system that was dependent on an intact PTAP motif.	1-(4-methylphenyl)propane-2-amine	100-104	tumor susceptibility 101	Homo sapiens	30-36
15044860-4	2004	The down-regulation of TSG101 could significantly enhance the sensitivity of SGC7901/VCR cells to vincristine and adriamycin.	Vincristine	98-109	tumor susceptibility 101	Homo sapiens	23-29
15044860-4	2004	The down-regulation of TSG101 could significantly enhance the sensitivity of SGC7901/VCR cells to vincristine and adriamycin.	Doxorubicin	114-124	tumor susceptibility 101	Homo sapiens	23-29
15044860-5	2004	The capacity of cells to efflux adriamycin markedly decreased in TSG101 siRNA transfectants.	Doxorubicin	32-42	tumor susceptibility 101	Homo sapiens	65-71
12802020-5	2003	TSG101/HRS interaction occurs between a ubiquitin-binding domain of TSG101 and two distinct proline-rich regions of HRS, and is modulated by a C-terminal TSG101 sequence that resembles a motif targeted in HRS.	Proline	92-99	tumor susceptibility 101	Homo sapiens	0-6
15126635-0	2004	Nedd4.1-mediated ubiquitination and subsequent recruitment of Tsg101 ensure HTLV-1 Gag trafficking towards the multivesicular body pathway prior to virus budding.	Glycosaminoglycans	83-86	tumor susceptibility 101	Homo sapiens	62-68
15126635-2	2004	The Gag proteins of oncoretroviruses possess a PPxY motif that recruits a ubiquitin ligase from the Nedd4 family, whereas those of the human immunodeficiency virus interact through a PTAP motif with Tsg101, a protein of the ESCRT-1 complex.	Glycosaminoglycans	4-7	tumor susceptibility 101	Homo sapiens	199-205
15126635-6	2004	We also demonstrate that Gag interacts first with Nedd4.1 at the plasma membrane and then with Tsg101 in late endosomes/MVBs.	Glycosaminoglycans	25-28	tumor susceptibility 101	Homo sapiens	95-101
15126635-8	2004	Our findings indicate that Nedd4.1 and Tsg101 act successively in the assembly process of HTLV-1 to ensure proper Gag trafficking through the endocytic pathway up to late endosomes where the late steps of retroviral release occur.	Glycosaminoglycans	114-117	tumor susceptibility 101	Homo sapiens	39-45
15053872-5	2004	Mutations that disrupt the interface inhibit MVB sorting, and the structure also explains how the TSG101 UEV can independently bind its ubiquitin and Pro-Thr/Ser-Ala-Pro peptide ligands.	prolylthreonine	150-157	tumor susceptibility 101	Homo sapiens	98-104
15053872-5	2004	Mutations that disrupt the interface inhibit MVB sorting, and the structure also explains how the TSG101 UEV can independently bind its ubiquitin and Pro-Thr/Ser-Ala-Pro peptide ligands.	Serine	158-161	tumor susceptibility 101	Homo sapiens	98-104
15053872-5	2004	Mutations that disrupt the interface inhibit MVB sorting, and the structure also explains how the TSG101 UEV can independently bind its ubiquitin and Pro-Thr/Ser-Ala-Pro peptide ligands.	Alanine	162-165	tumor susceptibility 101	Homo sapiens	98-104
13679614-6	2003	When cells were treated with colchicine, which interferes with microtubule polymerization, NS3 still associated with tubulin and TSG101.	Colchicine	29-39	tumor susceptibility 101	Homo sapiens	129-135
12915533-7	2003	Fractionation analysis and confocal examination both indicated that the N-terminal region of Tsg101, which contains binding sites for PTAP and ubiquitin (Ub), was required for Gag trafficking to the plasma membrane.	1-(4-methylphenyl)propane-2-amine	134-138	tumor susceptibility 101	Homo sapiens	93-99
12915533-8	2003	Expression of FLAG-tagged Tsg101 with a deletion in the Ub-binding pocket inhibited VLP release almost completely and to a significantly greater extent than expression of the wt tagged Tsg101 protein or Tsg101-FLAG containing a deletion in the PTAP-binding region.	1-(4-methylphenyl)propane-2-amine	244-248	tumor susceptibility 101	Homo sapiens	26-32
12915533-9	2003	The results demonstrate that Gag associates with endosomal trafficking compartments and indicate that efficient release of virus particles from the plasma membrane requires both the PTAP- and Ub-binding functions of Tsg101 to recruit the cellular machinery required for budding.	1-(4-methylphenyl)propane-2-amine	182-186	tumor susceptibility 101	Homo sapiens	216-222
12802020-5	2003	TSG101/HRS interaction occurs between a ubiquitin-binding domain of TSG101 and two distinct proline-rich regions of HRS, and is modulated by a C-terminal TSG101 sequence that resembles a motif targeted in HRS.	Proline	92-99	tumor susceptibility 101	Homo sapiens	68-74
12802020-5	2003	TSG101/HRS interaction occurs between a ubiquitin-binding domain of TSG101 and two distinct proline-rich regions of HRS, and is modulated by a C-terminal TSG101 sequence that resembles a motif targeted in HRS.	Proline	92-99	tumor susceptibility 101	Homo sapiens	68-74
11916981-3	2002	Both tumor susceptibility gene 101 (TSG101)/human VPS (hVPS)28 and hepatocyte growth factor receptor substrate (Hrs) cytosolic complexes bind ubiquitin-agarose.	Sepharose	152-159	tumor susceptibility 101	Homo sapiens	5-34
15043208-8	2003	Key area in the process include interactions with TSG101, L domain receptor which normally functions in the endosomal sorting pathway and with lipid rafts, a type of M domain receptor, which has been suggested to be the sites for effective concentration of Gag.	Glycosaminoglycans	257-260	tumor susceptibility 101	Homo sapiens	50-56
12006492-4	2002	We now report the structure of Tsg101 UEV and chemical shift mapping of the Ub and PTAP binding sites.	1-(4-methylphenyl)propane-2-amine	83-87	tumor susceptibility 101	Homo sapiens	31-37
11916981-3	2002	Both tumor susceptibility gene 101 (TSG101)/human VPS (hVPS)28 and hepatocyte growth factor receptor substrate (Hrs) cytosolic complexes bind ubiquitin-agarose.	Sepharose	152-159	tumor susceptibility 101	Homo sapiens	36-42
35579947-5	2022	Mechanistically, hnRNPA1 bound with SUMO2 at the lysine 113 residue via KRASG12D-induced hyperactivation of SUMOylation, which enabled its interaction with TSG101 to enhance hnRNPA1 packaging and transmission via EVs.	Lysine	49-55	tumor susceptibility 101	Homo sapiens	156-162
11805336-3	2002	Recently, it was demonstrated that the product of tumor susceptibility gene 101 (TSG101), which contains at its N terminus a domain highly related to ubiquitin-conjugating (E2) enzymes, binds HIV-1 Gag in a p6-dependent fashion.	Glycosaminoglycans	198-201	tumor susceptibility 101	Homo sapiens	81-87
34203832-2	2021	A highly conserved Pro-(Thr/Ser)-Ala-Pro (P(T/S)AP) motif in the HIV-1 structural polyprotein, Gag, engages a P(T/S)AP-binding pocket in the Tsg101 N-terminal domain.	pro-(thr	19-27	tumor susceptibility 101	Homo sapiens	141-147
34203832-2	2021	A highly conserved Pro-(Thr/Ser)-Ala-Pro (P(T/S)AP) motif in the HIV-1 structural polyprotein, Gag, engages a P(T/S)AP-binding pocket in the Tsg101 N-terminal domain.	ser)-ala-pro	28-40	tumor susceptibility 101	Homo sapiens	141-147
34203832-2	2021	A highly conserved Pro-(Thr/Ser)-Ala-Pro (P(T/S)AP) motif in the HIV-1 structural polyprotein, Gag, engages a P(T/S)AP-binding pocket in the Tsg101 N-terminal domain.	Glycosaminoglycans	95-98	tumor susceptibility 101	Homo sapiens	141-147
34203832-3	2021	Since the same domain in Tsg101 that houses the pocket was found to bind mono-ubiquitin (Ub) non-covalently, Ub binding was speculated to enhance P(T/S)AP interaction.	mono-ubiquitin	73-87	tumor susceptibility 101	Homo sapiens	25-31
34203832-3	2021	Since the same domain in Tsg101 that houses the pocket was found to bind mono-ubiquitin (Ub) non-covalently, Ub binding was speculated to enhance P(T/S)AP interaction.	BM	89-91	tumor susceptibility 101	Homo sapiens	25-31
34203832-3	2021	Since the same domain in Tsg101 that houses the pocket was found to bind mono-ubiquitin (Ub) non-covalently, Ub binding was speculated to enhance P(T/S)AP interaction.	BM	109-111	tumor susceptibility 101	Homo sapiens	25-31
34203832-3	2021	Since the same domain in Tsg101 that houses the pocket was found to bind mono-ubiquitin (Ub) non-covalently, Ub binding was speculated to enhance P(T/S)AP interaction.	Platinum	146-149	tumor susceptibility 101	Homo sapiens	25-31
34203832-3	2021	Since the same domain in Tsg101 that houses the pocket was found to bind mono-ubiquitin (Ub) non-covalently, Ub binding was speculated to enhance P(T/S)AP interaction.	Sulfur	150-152	tumor susceptibility 101	Homo sapiens	25-31
11595185-3	2001	The UEV domain of Tsg101 binds to an essential tetrapeptide (PTAP) motif within the p6 domain of the structural Gag protein and also to ubiquitin.	Glycosaminoglycans	112-115	tumor susceptibility 101	Homo sapiens	18-24
35315341-8	2022	Moreover, glutamate supplementation increased exosome secretion by increasing expression of Alix, TSG101, Rab27a/b and VAMP7.	Glutamic Acid	10-19	tumor susceptibility 101	Homo sapiens	98-104
35220706-24	2022	Exosomal markers including CD9 and TSG101 were positively presented on the dMSC exosomes.	doxycycline fosfatex	75-79	tumor susceptibility 101	Homo sapiens	35-41
35336929-7	2022	Furthermore, we demonstrated that the functional site of Alix is V498 in the V domain and the functional site of Tsg101 is N69 in the UBC-like domain for BFV budding.	1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione	134-137	tumor susceptibility 101	Homo sapiens	113-119